活跃治疗与预期治疗的专利管道动脉在早产婴儿:一个元分析
Santosi Buvaneswarran1,2, Yi Ling Wong2, Shen Liang3
1Department of Neonatology, Khoo Teck Puat National University Children's Medical Institute, National University Hospital, National University Health System, Singapore.
JAMA pediatrics
|May 27, 2025
概括
在早产婴儿中,专用动脉管 (PDA) 的积极治疗增加了死亡或支气管肺张力 (BPD) 和死亡率. 预期管理可能为血液动力学上显著的PDA提供更好的结果.
科学领域:
- 新生儿科学 新生儿科学
- 儿童心脏病学 儿童心脏病学
- 临床研究 临床研究
背景情况:
- 血液动力学上显著的专利动脉管 (PDA) 在早产婴儿中很常见.
- 有证据表明,期望治疗可能会比积极治疗产生更好的结果.
- 在早产婴儿中PDA的最佳管理策略需要进一步研究.
研究的目的:
- 为了比较活跃治疗与预期管理的临床结果,在早产婴儿中对血液动力学上显著的PDA进行比较.
- 评估不同PDA管理策略对死亡率和发病率的影响.
主要方法:
- 在PubMed,Embase和Cochrane图书馆系统搜索2010年1月至2024年7月期间发表的随机临床试验 (RCT).
- 包括注册早产婴儿 (怀孕33周前出生) 的RCT,比较主动治疗和预期管理.
- 分析使用随机效应模型汇集了10个涉及2035名婴儿的RCT的数据.
主要成果:
- 积极的PDA治疗与较高的死亡率或中度至严重的支气管肺功能障碍 (BPD) 相关 (56.2% vs 50.8%).
- 在36周的死亡率在积极治疗组显著更高 (14.3%对11.2%).
- 两组之间在中度至重度的BPD或周周结节性白血病 (PVL) 发生率上没有发现显著差异.
结论:
- 在生命的前两周内积极治疗血液动力学显著的PDA与增加的死亡率和BPD有关.
- 与积极治疗相比,预期治疗似乎与更好的结果有关.
- 需要进一步的研究来完善用于管理早产新生儿PDA的临床方案.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
228
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
228
01:25Aortic Regurgitation III: Medical Management
53
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
53